Shabo et al reported that cancer cells expressing CD163 were associated with poor prognosis in patients with breast cancer [41] and rectal cancer, [42] and the CD163+ cancer cells were deemed as the fusion of cancer cells and macrophages and could be more radiation resistant or more aggressive. This evidence concerns the gene CD163 and breast cancer.